AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

cMET-SURE: A Novel, Sensitive, and Specific Platform for Cancer Diagnosis

Detailed Technology Description: None

Others

*Abstract: UNIVERSITY OF MISSOURIOffice of Technology Management and Industry RelationsNon-Confidential Abstract of InventionUM Disclosure Numbers 15UMC011INNOVATION:This invention is a gold nanorod-based tissue diagnostic agent specific for the c-Met receptor, a biomarker of many cancers. The gold nanorod diagnostic agent is targeted using a peptide with specific affinity for the c-Met cell surface receptor. The gold nanorod-peptide complex binds the c-Met receptor to give a direct signal, rather than the indirect signal provided by standard antibody-based methods, enabling improved sensitivity and accuracy of quantitation. Since it is a direct quantitation, it also requires less time and fewer steps, resulting in an improvement over current immunohistochemical methods.BACKGROUND:Personalized medicine is an attractive option for cancer treatment due to the specificity of biomarker-targeted therapies. To treat a patient with targeted drugs, a biopsy must be tested to establish a profile of suitable biomarker targets. One such attractive biomarker is hepatocyte growth factor (HGF) receptor, also known as c-Met. c-Met is overexpressed in many types of cancer, including non-small cell lung carcinoma (NSCLC), gastric, ovarian, thyroid, breast, colon and other cancers. Current methods of evaluating c-Met expression have not had sufficient sensitivity or accuracy to warrant clinical diagnosis. APPLICATIONs:- Detection, imaging, and quantitation of c-Met in tissue samples- Personalized medicine for various cancersADVANTAGES:- Faster and simpler diagnostic than current antibody-based assays- Modifications to the targeting peptide enhance interaction with receptors- Quantifiable results that can be used for diagnosis as well as treatment decision makingSTAGE OF DEVELOPMENT:- PreclinicalPATENT STATUS:- Patents filedINVENTORS:- Raghuraman Kannan- Charles Caldwell- Gerald ArthurCONTACT INFO:Brian Buntaine, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry RelationsEmail: buntaineb@missouri.eduPhone: 573-882-0470

*Principal Investigator: Name: Raghuraman Kannan
Department:

Name: Charles (Chuck) Caldwell, Graduate Student, Biological Engr & Radiology
Department:

Name: Gerald Arthur, Research Assistant Professor
Department:

Country/Region: USA

For more information, please click Here